DIFFERENCE IN BLOOD FUNCTION TOXICITY BETWEEN STADIUM IIB-IIIB SQUAMOUS CELL CERVICAL CANCER PATIENTS WITH PACLITAXEL CISPLATIN AND PACLITAXEL CARBOPLATIN CHEMOTHERAPY AT SANGLAH HOSPITAL, DENPASAR.


Indrayathi Pa, Noviyani R, Niruri R, Budiana Ing, Tunas K

Abstract


 Objective: Paclitaxel cisplatin and paclitaxel carboplatin were chemotherapy regimens used for cervical cancer treatments at Sanglah Hospital, Denpasar. They came with hematologic toxicity side effects. This could be monitored from hemoglobin, thrombocyte, and leukocyte parameter. Data that compared the toxicity of these two regimens were still limited at Sanglah Hospital, Denpasar. Therefore, it was necessary to conduct a research about the difference in blood function toxicity between patients who underwent paclitaxel cisplatin chemotherapy and those who underwent paclitaxel carboplatin chemotherapy based on those three parameters.

Methods: This was a prospective observational research with consecutive sampling, inclusion, and exclusion criteria. It was carried out from January to August 2016 at Sanglah Hospital, Denpasar. Patients were categorized into two groups based on their chemotherapy regimens. Next, blood samples from both groups were tested for its hemoglobin, thrombocyte, and leukocyte level before and after chemotherapy. The data underwent normality test using either Shapiro–Wilk or Mann–Whitney test with SPSS.

Results: There were 17 patients who fulfilled the inclusion criteria. The result showed a decrease in hemoglobin, thrombocyte, as well as leukocyte values in patients who underwent paclitaxel cisplatin and paclitaxel carboplatin chemotherapy.

Conclusion: The decrease of both hemoglobin and leukocyte level was not meaningful in both groups (p>0.05). Meanwhile, the decrease of thrombocyte level was meaningful in both groups (*p<0.05) in which patients who belong to paclitaxel carboplatin chemotherapy group showed a higher decrease of thrombocyte values.


Keywords


Chemotherapy, Cervical cancer, Paclitaxel cisplatin, Paclitaxel carboplatin, Hemoglobin, Thrombocyte, Leukocyte.

| PDF |

References


Kemenkes RI. (Kementrian Kesehatan Republik Indonesia). Pusat Data dan Informasi Kementrian Kesehatan RI. Jakarta: Kementerian Kesehatan Republik Indonesia; 2015a.

Kemenkes RI. Panduan Pelayanan Klinis Kanker Serviks. Jakarta: Kementerian Kesehatan Republik Indonesia; 2015b.

Skeel RT, Khleif SN. Handbook of Cancer Chemotherapy. 8th ed. Philladelphia, PA: Lippincot William and Wilkins, A Wolters Kluwer Business; 2011. p. 118-25.

Komite Medik RSUP Sanglah. Protokol Kemoterapi Onkologi Ginekologi. Denpasar: Rumah Sakit Umum Pusat Sanglah; 2011.

Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: A gynecologic oncology group study. J Clin Oncol 2004;22:3113-9.

Hoskins WJ, Perez CA, Young RC. Principles and Practice of Gynecologic Oncology. 4th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2005.

Kitagawa R, Katsumata N, Shibata T, Kamura T, Kasamatsu T, Nakanishi T, et al. Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: The open-label randomized Phase III Trial JCOG0505. J Clin Oncol 2015;33:2129-35.

Andrijono AF, Saiffudin AB. Buku Acuan Nasional Onkologi Ginekologi. Jakarta: Yayasan Bina Pustaka Sarwono Prawirohardjo; 2006.

Anderson PO, Knoben JE, Troutman WG. Handbook of Clinical Drug Data. 10th ed. USA: McGraw-Hill Companies, Inc; 2002.

Smith IE, O’Brien ME, Talbot DC, Nicolson MC, Mansi JL, Hickish TF, et al. Duration of chemotherapy in advanced non-small-cell lung cancer: A randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 2001;19:1336-43.

Herfindal ET, Gourley DR. Textbook of Therapeutics Drugs and Disease Management. USA: Lippincott Williams & Wilkins; 2000.

WHO (World Health Organization). Comprehensive Cervical Cancer Control A Guide to Essential Practice. Switzerland: World Health Organization; 2014.

Lasut E, Rarung M, Suparman E. Karakteristik penderita kanker serviks di BLU RSUP Prof. Dr. R. D. Kandou. J e-Clin 2015;3:83-6. Available from:https://www.ejournal.unsrat.ac.id/index.php/eclinic/article/view/6519.

Dandal A, Abajy MY, Alkhalaf M, Ibrahim A. Prevalence of human papilloma virus Types 16 And 18 among women with cervical cancer in aleppo, Syria. Int J Pharm Sci 2017;9:90-3. Available from: https://www.innovareacademics.in/journals/index.php/ijpps/article/view/18773/12125.

Pandey D, Shetty J, Sambhaji C, Saxena PU, Mishra D, Chawla A. Cervical Cancer as a silent killer: A rare case report with review of literature. J Cancer Res Ther 2015;11:653.

Antony A, Joel JJ, Shetty J, Umar NF. Identification and analysis of adverse drug reactions associated with cancer chemotherapy in hospitalized patients. Int J Pharm Sci 2016;8:448-51. Available from: http://www.innovareacademics.in/journals/index.php/ijpps/article/view/11601/6208.

Park DC, Kim JH, Lew YO, Kim DH, Namkoong SE. Phase II trial of neoadjuvant paclitaxel and cisplatin in uterine cervical cancer. Gynecol Oncol 2004;92:59-63.

Mell LK, Kochanski JD, Roeske JC, Haslam JJ, Mehta N, Yamada SD, et al. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. Int J Radiat Oncol Biol Phys 2006;66:1356-65.

Umayahara K, Takekuma M, Hirashima Y, Noda SE, Ohno T, Miyagi E, et al. Phase II study of concurrent chemoradiotherapy with weekly cisplatin and paclitaxel in patients with locally advanced uterine cervical cancer: The JACCRO GY-01 trial. Gynecol Oncol 2016;140:253-8.

Rodgers GM. Managing patients with chemotherapy-induce anemia. Adv Stud Med 2008;8:346-51. Available from: http://www.qu.edu.qa//2B_Chemotherapy-Induced_Anemia.pdf.

El-Deen DS, Al-Shahat M, El-Metwaly AE. Weekly paclitaxel and carboplatin for patients with advanced ovarian cancer. Med J Cairo Univ 2012;8025-31. Available from http//www.erepository.cu.edu.eg/index.php/MJCU/article/view/977/954.

Handayani W, Haribowo AS. Buku Ajar Asuhan Keperawatan pada Klien dengan Gangguan Sistem Hematologi. Jakarta: Salemba Medika; 2008.

DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: A Pathophysiologic Approach. 5th ed. United States of America: The McGraw-Hill Companies, Inc; 2002.

Kee JL, Hayes ER. Farmakologi: Pendekatan Proses Keperawatan. Jakarta: Penerbit Buku Kedokteran EGC; 1994.

Dollery C. Therapeutic Drugs. 2nd ed. United Kingdom: Churchill Livingstone; 1999.

Joseph S, Pradeep S, Jayakumar KL. A prospective comparative study of the toxicity profile in patients receiving cisplatin-paclitaxel vs carboplatin-paclitaxel in advanced ovarian cancer. Int J Med Pharm Sci 2015;6:1-5. Available from: http://www.scopemed.org/?mno=205116.

Rosell R, Gatzemeier U, Betticher DC, Keppler U, Macha HN, Pirker R, et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: A cooperative multinational trial. Ann Oncol 2002;13:1539-49.

du Bois A, Lück HJ, Meier W, Adams HP, Möbus V, Costa S, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003;95:1320-9.

Gibson J. Fisiologi dan Anatomi Modern untuk Perawat. Jakarta: ECG; 2003.

Sweetman SC. Martindale: The Complete Drug Reference. 36th ed. London: Pharmaceutical Press; 2009.

Panichevaluk A. Phase II study of paclitaxel plus carboplatin in recurrent and/or metastatic cervical carcinoma. Thai J Obstet Gynaecol 2003;15:33-7. Available from: http://www.tci-thaijo.org/index.php/tjog/article/view/82779.

Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194-200.

Cassidy J, Bissett D, Obe RA. Oxford Handbook of Oncology. New York: Oxford University Press; 2002.




About this article

Title

DIFFERENCE IN BLOOD FUNCTION TOXICITY BETWEEN STADIUM IIB-IIIB SQUAMOUS CELL CERVICAL CANCER PATIENTS WITH PACLITAXEL CISPLATIN AND PACLITAXEL CARBOPLATIN CHEMOTHERAPY AT SANGLAH HOSPITAL, DENPASAR.

Topics

Pharmacy; Clinical pharmacy

Keywords

Chemotherapy, Cervical cancer, Paclitaxel cisplatin, Paclitaxel carboplatin, Hemoglobin, Thrombocyte, Leukocyte.

DOI

10.22159/ajpcr.2018.v11i1.22125

Date

01-01-2018

Additional Links

Manuscript Submission

Journal

Asian Journal of Pharmaceutical and Clinical Research
Vol 11 Issue 1 January 2018 Page: 224-227

Print ISSN

0974-2441

Online ISSN

2455-3891

Authors & Affiliations

Indrayathi Pa
Department of Public Health, Faculty of Medicine, Udayana University, Bali, Indonesia.
Indonesia

Noviyani R
Department of Pharmacy, Faculty of Mathematics and Sciences, Udayana University, Bali, Indonesia.
Indonesia

Niruri R
Department of Pharmacy, Faculty of Mathematics and Sciences, Udayana University, Bali, Indonesia.
Indonesia

Budiana Ing
Department of Obstetrics and Gynecology, Faculty of Medicine, Udayana University, Bali, Indonesia.
Indonesia

Tunas K
Department of Public Health, Faculty of Health, Science and Technology, Dhyana Pura University, Bali,Indonesia.
Indonesia


Article Tools


Email this article (Login required)
Email the author (Login required)

Refbacks

  • There are currently no refbacks.